Rabbit Recombinant Monoclonal TL1A antibody. Suitable for IP, WB and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
IP | Flow Cyt | WB | IHC-P | ICC/IF | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Tested | Not recommended | Not recommended |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/30 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Human, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Human, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Human, Rat | Dilution info - | Notes - |
Select an associated product type
Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis.
TL1, VEGI, TNFSF15, Tumor necrosis factor ligand superfamily member 15, TNF ligand-related molecule 1, Vascular endothelial cell growth inhibitor
Rabbit Recombinant Monoclonal TL1A antibody. Suitable for IP, WB and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
The protein TL1A also known as TNF-like ligand 1A is part of the tumor necrosis factor (TNF) superfamily. It is a cytokine with a molecular weight of approximately 23 kDa. Cells such as endothelial cells monocytes and fibroblasts express TL1A. TL1A predominantly acts as ligand for death receptor 3 (DR3) also called TNFRSF25 and is involved in immune response regulation. This protein can be found mainly in tissues involved in immune surveillance like lymph nodes and the gastrointestinal tract.
TL1A interacts to induce T cell proliferation and cytokine production. It forms a complex with DR3 to activate downstream signaling pathways. These activities enhance adaptive immunity by stimulating T helper cells. Furthermore TL1A influences the production of inflammatory cytokines like interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α). Through its interaction with DR3 TL1A modulates important immune responses.
TL1A features in the TNF receptor-mediated signaling and the NF-kB signaling pathway. In these pathways it links to proteins such as RIPK1 and TRAF2. The signaling through DR3 influences cell survival differentiation and apoptosis. These pathways are important in maintaining the balance between immune activation and tolerance. By interacting with various signaling molecules TL1A orchestrates complex immune functions that ensure adequate immune responses and prevent autoimmunity.
Researchers connect TL1A with conditions like inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). These conditions involve chronic inflammation and immune dysregulation where TL1A plays a role. In IBD elevated TL1A levels drive inflammation in the intestines. In RA TL1A potentially interacts with fibroblast-like synoviocytes contributing to joint inflammation and damage. Its relation to DR3 further implicates TL1A in these autoimmune disorders making it a target for therapeutic interventions aiming to mitigate immune-mediated damage.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
TL1A was immunoprecipitated from 0.35 mg HT-29 (human colorectal adenocarcinoma epithelial cell), whole cell lysate with ab270456 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab270456 at 270456 dilution. VeriBlot for IP Detection Reagent (HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/1000 dilution.
Lane 1: HT-29 (human colorectal adenocarcinoma epithelial cell), whole cell lysate 10 ug
Lane 2: ab270456 IP in HT-29 whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab270456 in mouse ovary tissue lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 32 seconds
All lanes: Immunoprecipitation - Anti-TL1A antibody [EPR23330-2] (ab270456)
Predicted band size: 28 kDa
Observed band size: 25-36 kDa
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
TL1A is a glycoprotein, the molecular weight observed is consistent with what has been described in literature (PMID 20675618).
Negative control: MCF7 (PMID: 9434163 ).
This blot was developed using a higher sensitivity ECL substrate.
All lanes: Western blot - Anti-TL1A antibody [EPR23330-2] (ab270456) at 1/1000 dilution
Lane 1: HT-29 (human colorectal adenocarcinoma epithelial cell), whole cell lysate at 40 µg
Lane 2: MCF7 (human breast adenocarcinoma epithelial cell), whole cell lysate at 40 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 28 kDa
Observed band size: 25-36 kDa
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 59 seconds.
TL1A is a glycoprotein, the molecular weight observed is consistent with what have been described in literature (PMID 20675618).
The expression of TL1A is induced by TNFa in HUVEC (PMID: 15847792).
All lanes: Western blot - Anti-TL1A antibody [EPR23330-2] (ab270456) at 1/1000 dilution
Lane 1: HUVEC (human umbilical vein endothelial cell), whole cell lysate at 20 µg
Lane 2: HUVEC treated with/ml TNF-alpha for 24 hours, whole cell lysate 20 at 10 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 28 kDa
Observed band size: 25-36 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com